Overview
FOXO4-DRI is a D-Retro-Inverso peptide developed at Erasmus University Medical Center in the Netherlands. It is designed to target and eliminate senescent cells, which accumulate with age and contribute to aging phenotypes. Senescent cells can secrete inflammatory factors and inhibit tissue repair, contributing to age-related decline.
This peptide functions by disrupting the interaction between FOXO4 and p53 proteins. By preventing FOXO4 from sequestering p53, the peptide allows p53 to trigger apoptosis specifically in senescent cells, leading to their elimination without harming healthy, dividing cells. This targeted approach aims to reduce the burden of senescent cells and improve overall tissue function.
The D-Retro-Inverso modification (using D-amino acids in reverse sequence) provides resistance to proteolytic degradation, increasing the peptide's stability and duration of action within the body. This modification is crucial for maintaining the peptide's ability to interfere with the target protein interaction over an extended period.
Mechanism of Action
FOXO4-DRI works by selectively inducing apoptosis in senescent cells. Senescent cells evade apoptosis by using the FOXO4 protein to bind and sequester p53 within the nucleus. This interaction prevents p53 from initiating cell death pathways, allowing senescent cells to persist and accumulate in tissues.
FOXO4-DRI disrupts this interaction by competitively binding to p53. The peptide's modified sequence enables it to enter senescent cells and displace endogenous FOXO4, freeing p53 to activate apoptotic pathways. This release of p53 triggers the activation of cell death proteins, such as BAX and PUMA, leading to the selective elimination of senescent cells.
The D-Retro-Inverso modification is critical for the peptide's function. It ensures that the peptide maintains its binding affinity for p53 while also resisting degradation by proteases. This increased stability allows the peptide to exert its therapeutic effects over a longer period, enhancing its ability to target and eliminate senescent cells within complex tissue environments.
Key Benefits
- Senescent Cell Clearance
- Age-Related Phenotype Improvement
- FOXO4-p53 Disruption
- Chemotherapy Recovery Enhancement
- Tissue Regeneration Support
Research & Indications
Research indicates that FOXO4-DRI may have several potential applications. Studies have shown its ability to selectively eliminate senescent cells, leading to improvements in age-related phenotypes and tissue function. Animal studies have demonstrated that treatment with FOXO4-DRI can improve physical activity levels, fur quality, and kidney function in aged mice.
Additionally, FOXO4-DRI has shown potential in accelerating recovery from chemotherapy-induced damage. Chemotherapy drugs can induce cellular senescence in healthy tissues, leading to long-term side effects. Research suggests that FOXO4-DRI treatment may help reduce these side effects by eliminating the senescent cells that accumulate following chemotherapy.
Furthermore, studies suggest that FOXO4-DRI may enhance tissue regeneration capacity. By removing senescent cells that inhibit stem cell function and tissue repair mechanisms, the peptide may create a more permissive environment for endogenous stem cell activation and tissue renewal. This could lead to improvements in organ function and physical capacity.
Dosing Protocols
Disclaimer: The following dosing information is for research purposes only and does not constitute medical advice. Consult with a qualified healthcare professional before using FOXO4-DRI.
Typical dosing for research purposes:
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Senescent Cell Clearance | 2-5mg | 2x weekly | SubQ or IM |
If applicable, include a gradual titration schedule:
| Phase | Daily Dose | Frequency |
|---|---|---|
| Weeks 1-2 | 500mcg | Once daily |
Supplies Needed
For an 8-16 week protocol:
- Peptide Vials: 4-10 vials of 10mg each
- Insulin Syringes (U-100): 16-32 syringes per week, 128-512 total
- Bacteriostatic Water: 2-3 × 10mL bottles
- Alcohol Swabs: One for vial + one for injection site daily
Side Effects & Safety
Side effects and safety considerations for FOXO4-DRI are not extensively documented in human studies. As a research peptide, its long-term effects are not fully understood. Potential side effects may include injection site reactions (redness, swelling, pain), allergic reactions, or unforeseen effects on cellular processes. It is essential to conduct thorough research and consult with a qualified healthcare professional before considering the use of FOXO4-DRI.
Storage & Handling
Store FOXO4-DRI at -20°C or below to maintain its stability and integrity. Prior to use, the peptide should be reconstituted with bacteriostatic water. Once reconstituted, it should be stored at 2-8°C and used within a reasonable timeframe (e.g., within a few weeks) to minimize degradation.